Regenerative Medical Technology Group (RMTG) AI Stock Analysis

Regenerative Medical Technology Group

(Other OTC:RMTG)

Select Model

Rating:41Neutral

Price Target:$0.03▼(-5.88% Downside)

Action:reiterated

Date:10/31/26

The score is primarily constrained by stressed financials—large net losses, negative equity, leverage risk, and negative free cash flow—despite strong revenue growth and solid gross margins. Technicals also weigh on the score given a downtrend across moving averages, even with oversold readings. Corporate-event commentary is mildly supportive on growth strategy but tempered by acknowledged liabilities and financing pressure.

Positive Factors

Revenue GrowthRapid revenue expansion indicates strong demand across the company’s regenerative medicine activities and related platforms. If maintained, this scale can improve operating leverage, broaden clinical and educational reach, and create a larger base from which recurring products and services can develop.

Negative Factors

Sustained Net LossesThe company’s substantial net loss shows that current revenue and gross profit are not yet sufficient to cover its full cost structure and other charges. Continued losses could consume capital, restrict investment flexibility, and delay the point at which growth translates into durable shareholder value.

Regenerative Medical Technology Group (RMTG) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $467.13K
Dividend Yield: ―
Average Volume (3M): 60.65K
Price to Earnings (P/E): -0.0
Beta (1Y): -1.72
Revenue Growth: 94.32%
EPS Growth: -158.38%
Country: US
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Regenerative Medical Technology Group Business Overview & Revenue Model

Company Description

Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of st...

Regenerative Medical Technology Group Financial Statement Overview

Summary

Strong TTM revenue growth (~47.7%) and solid gross margin (~59.8%) show improving operations, including a small positive EBIT. However, the overall profile remains high risk due to a large TTM net loss (~-$9.5M, ~-101% net margin), negative equity (about -$39.3M), rising debt (~$21.7M) versus a small asset base (~$5.9M), and still-negative free cash flow (about -$0.58M).

Income Statement

34Negative

Balance Sheet

18Very Negative

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	9.41M	5.10M	4.11M	2.41M	1.53M	437.89K
Gross Profit	5.51M	2.81M	2.82M	1.68M	876.97K	150.14K
EBITDA	2.00M	-83.56K	301.74K	-3.01M	-1.02M	-10.11M
Net Income	-9.53M	-7.81M	-5.56M	-9.81M	-5.49M	-12.88M
Balance Sheet
Total Assets	5.85M	4.49M	3.82M	2.88M	8.08M	9.31M
Cash, Cash Equivalents and Short-Term Investments	1.32M	956.72K	1.17M	530.54K	1.65M	2.98M
Total Debt	21.74M	19.57M	20.05M	17.65M	15.14M	13.37M
Total Liabilities	45.11M	39.23M	31.18M	24.67M	20.06M	16.06M
Stockholders Equity	-39.26M	-34.75M	-27.36M	-21.80M	-11.98M	-6.76M
Cash Flow
Free Cash Flow	-582.33K	-1.31M	635.28K	-804.80K	-1.31M	-9.88M
Operating Cash Flow	268.56K	-706.52K	850.70K	-419.20K	-1.11M	-9.88M
Investing Cash Flow	-850.89K	-602.58K	-215.42K	-385.60K	-198.43K	666.47K
Financing Cash Flow	291.38K	1.10M	0	-309.85K	-20.78K	12.15M

Regenerative Medical Technology Group Technical Analysis

Technical Analysis SentimentNegative

Last Price0.03

Price Trends

50DMA0.07Negative

100DMA0.06Negative

200DMA0.05Negative

Market Momentum

MACD-0.01Positive

RSI25.28Positive

STOCH11.11Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RMTG, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.07, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 25.28 is Positive, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RMTG.

Regenerative Medical Technology Group Risk Analysis

Regenerative Medical Technology Group disclosed 37 risk factors in its most recent earnings report. Regenerative Medical Technology Group reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Regenerative Medical Technology Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

RMTG against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BJDX	44Neutral	$2.49M	-0.05	-125.01%	―	―	93.91%
IVF	43Neutral	$2.28M	-0.06	-47.41%	―	13.76%	99.18%
WOK	43Neutral	$4.47M	-0.00	-18.55%	―	―	―
RMTG	41Neutral	$467.13K	-0.04	27.29%	―	94.32%	-158.38%

* Healthcare Sector Average

Performance Comparison

RMTG and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
RMTG	Regenerative Medical Technology Group Inc.	0.03	-0.01	-22.73%
BBLG	Bone Biologics Corp	0.38	-1.66	-81.37%
IVF	Invo Fertility Inc	1.91	-83.47	-97.76%
BJDX	Bluejay Diagnostics, Inc.	0.56	-6.56	-92.19%
NIVF	Newgenivf Group Limited	0.98	-10522.54	-99.99%
WOK	WORK Medical Technology Group LTD	1.00	-32799.00	-100.00%

Regenerative Medical Technology Group Corporate Events

Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresShareholder Meetings

Regenerative Medical Technology Group Highlights Growth, Financing Strategy

Positive

Aug 25, 2026

On August 20, 2026, Regenerative Medical Technology Group held a previously announced investor video call in which management addressed shareholder questions about growth, financing, and strategic direction. Executives highlighted strong revenue mome...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Regenerative Medical Technology Group AI Stock Analysis